Facioscapulohumeral Muscular Dystrophy (FSHD)

all catalysts(0)

nothing on the calendar yet

News(4)

• Epicrispr, Infinimmune snag combined $165M in VC cash
  Epicrispr Biotechnologies is working on an epigenetic medicine for facioscapulohumeral muscular dystrophy, while Infinimmune will advance a pair of antibodies for atopic dermatitis.
  biospace · 21h ago
• Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease
  The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.
  biopharma_dive · 21h ago
• Epicrispr raises $90M to rewrite treatment of rare muscle disease
  Epicrispr Biotechnologies has raised $90 million in a series C round backed by investors including Sanofi Ventures, positioning the biotech to advance a pipeline of epigenetic medicines led by an e…
  fiercebiotech · 23h ago
• 4 potential biotech M&A targets, plus a pretty sure bet from J&J
  Pharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.
  biospace · 7d ago